This is the authors' abstract. We don't add key points for this paper.
The loss of central nicotinic receptors is a neurochemical hallmark of several degenerative brain disorders, notably Alzheimer's (AD) and Parkinson's Disease (PD). Investigation of the effects of nicotinic agents in both normal and diseased individuals has produced strong evidence of the importance of the integrity of these systems for normal cognitive functioning. Studies in our laboratory utilizing the nicotinic antagonist mecamylamine show that blockade of nicotinic receptors produces measurable and significant cognitive impairment similar in nature to deficits seen in dementing illnesses. This work suggests that symptoms of impaired acquisition of information and short-term storage, impaired memory consolidation, attention, visual perception, and speed may reflect nicotinic lesions. These studies and others have suggested that nicotinic systems may be involved in the modulation, partitioning, and maintenance of attention, especially for tasks involving working memory, e.g. nicotinic systems may help constrain the focus of attention. Recent studies with nicotine in AD patients reviewed here suggest that nicotinic stimulation can improve the acquisition and retention of verbal information and decrease errors. Finally a review of attentional deficits in AD and PD is presented as a suggested target for nicotinic intervention. Further work will attempt to examine whether nicotinic augmentation effects attentional systems, mnemonic systems, or both as well as whether chronic stimulation with nicotine or novel agonists will produce clinical benefit. Drug Dev. Res. 38:278–289 © 1996 Wiley-Liss, Inc.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Newhouse et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: